The combination of DC101 with anti-PD-L1 antibodies promotes the formation of high endothelial venules in mouse BC, enabling intratumor infiltration of cytotoxic T cells and thereby sensitizing BCs to anti-PD-L1 therapy [131]. Here, CD274 is linked to breast cancer.